Antares Pharma, Inc. (ATRS)

EBITDA Margin

33.11%

TTM · Period ending:

ATRS logo

ATRS EBITDA Margin

Latest reported33.11%
ATRS TTM EBITDA Margin (-57.79% → 33.11%)
High-resolution chart · PNG

ATRS ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Antares Pharma, Inc. EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-54.1119%
-57.7876%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.